In 2023, CAR-T cells secreting BiTEs were designed to target two tumor antigens highly expressed in ovarian cancer cells: the cell surface Muc16 (4H11) and the intracellular Wilms tumor 1 (ESK1). The gene discussed is MUC16; the disease is ovarian cancer.